Status:

COMPLETED

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

Lead Sponsor:

University of Missouri-Columbia

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

45-64 years

Phase:

PHASE2

Brief Summary

The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.

Detailed Description

Twenty subjects will complete five days of treatment with zanamivir. Baseline measurements will be taken before the initiation of treatment, as well as after the conclusion of the treatment period (i....

Eligibility Criteria

Inclusion

  • Men and women with a BMI of 25-39 kg/m2
  • Ages 45-64 years at randomization.
  • Diagnosis of T2D classified based on physician diagnosis.
  • No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.

Exclusion

  • Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
  • History of chronic renal or hepatic disease
  • Active cancer
  • Autoimmune diseases
  • Immunosuppressant therapy
  • Hormone replacement therapy
  • Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
  • Current tobacco use
  • Pregnancy (Premenopausal women will be required to complete a urine pregnancy test before participation)
  • History of asthma or chronic obstructive pulmonary disease.
  • History of allergic reaction to lactose or milk proteins
  • Intranasal live attenuated influenza vaccine (LAIV) given within 2 weeks before zanamivir administration or a planned dose within 48 hours after zanamivir administration. Product insert states to avoid zanamivir administration with intranasal live attenuated influenza vaccine (LAIV).

Key Trial Info

Start Date :

July 14 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 18 2024

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT04867707

Start Date

July 14 2021

End Date

October 18 2024

Last Update

April 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Missouri, School of Medicine Clinical Research Center

Columbia, Missouri, United States, 65212

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes | DecenTrialz